Lung hilum neoplasm

Summary

Lung hilum neoplasm (MONDO:0003639) is a cancer. A subtype of lung neoplasm — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Classification: Cancer

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	lung hilum neoplasm
Mondo ID	MONDO:0003639
DOID	DOID:5767
NCIT	C5671
SNOMED CT	126707007
UMLS	C1290358
MedGen	224849
Anatomy (UBERON)	UBERON:0004886
Is cancer (heuristic)	yes

Also known as: hilar lung neoplasm · hilar lung tumor · hilar lung tumour · lung hilum neoplasm · lung hilum tumor · lung hilum tumour · lung hilus neoplasm · lung hilus neoplasm (disease) · lung hilus tumor · lung hilus tumour · neoplasm of lung hilus · tumor of lung hilus · tumour of lung hilus

Disease family

This is a subtype of lung neoplasm. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › respiratory system disorder › lower respiratory tract disorder › lung disorder › lung neoplasm › lung hilum neoplasm

Related subtypes (9): lung benign neoplasm, lung neuroendocrine neoplasm, lung cancer, Langerhans cell histiocytosis specific to adulthood, lung PEComa, fibroma of lung, hamartoma of lung, pulmonary sulcus neoplasm, lung germ cell tumor

Subtypes (1): lung hilum cancer

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 0.